| Title : An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials - Ligueros-Saylan_2010_Diabetes.Obes.Metab_12_495 |
| Author(s) : Ligueros-Saylan M , Foley JE , Schweizer A , Couturier A , Kothny W |
| Ref : Diabetes Obes Metab , 12 :495 , 2010 |
| Abstract : |
| PubMedSearch : Ligueros-Saylan_2010_Diabetes.Obes.Metab_12_495 |
| PubMedID: 20518805 |
| Title : Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects - He_2008_J.Clin.Pharmacol_48_85 |
| Author(s) : He YL , Ligueros-Saylan M , Sunkara G , Sabo R , Zhao C , Wang Y , Campestrini J , Pommier F , Dole K , Marion A , Dole WP , Howard D |
| Ref : Journal of Clinical Pharmacology , 48 :85 , 2008 |
| Abstract : |
| PubMedSearch : He_2008_J.Clin.Pharmacol_48_85 |
| PubMedID: 17986525 |
| Title : Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes - Azuma_2008_J.Clin.Endocrinol.Metab_93_459 |
| Author(s) : Azuma K , Radikova Z , Mancino J , Toledo FG , Thomas E , Kangani C , Dalla Man C , Cobelli C , Holst JJ , Deacon CF , He Y , Ligueros-Saylan M , Serra D , Foley JE , Kelley DE |
| Ref : J Clinical Endocrinology Metab , 93 :459 , 2008 |
| Abstract : |
| PubMedSearch : Azuma_2008_J.Clin.Endocrinol.Metab_93_459 |
| PubMedID: 18042650 |
| Title : Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes - Serra_2008_Int.J.Clin.Pharmacol.Ther_46_349 |
| Author(s) : Serra D , He YL , Bullock J , Riviere GJ , Balez S , Schwartz S , Wang Y , Ligueros-Saylan M , Jarugula V , Dole WP |
| Ref : Int J Clinical Pharmacology & Therapeutics , 46 :349 , 2008 |
| Abstract : |
| PubMedSearch : Serra_2008_Int.J.Clin.Pharmacol.Ther_46_349 |
| PubMedID: 18793589 |
| Title : The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients - Balas_2007_J.Clin.Endocrinol.Metab_92_1249 |
| Author(s) : Balas B , Baig MR , Watson C , Dunning BE , Ligueros-Saylan M , Wang Y , He YL , Darland C , Holst JJ , Deacon CF , Cusi K , Mari A , Foley JE , DeFronzo RA |
| Ref : J Clinical Endocrinology Metab , 92 :1249 , 2007 |
| Abstract : |
| PubMedSearch : Balas_2007_J.Clin.Endocrinol.Metab_92_1249 |
| PubMedID: 17244786 |
| Title : The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin - He_2007_Eur.J.Clin.Pharmacol_63_677 |
| Author(s) : He YL , Sabo R , Campestrini J , Wang Y , Ligueros-Saylan M , Lasseter KC , Dilzer SC , Howard D , Dole WP |
| Ref : European Journal of Clinical Pharmacology , 63 :677 , 2007 |
| Abstract : |
| PubMedSearch : He_2007_Eur.J.Clin.Pharmacol_63_677 |
| PubMedID: 17486328 |
| Title : Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects - He_2007_Curr.Med.Res.Opin_23_1131 |
| Author(s) : He YL , Sabo R , Riviere GJ , Sunkara G , Leon S , Ligueros-Saylan M , Rosenberg M , Dole WP , Howard D |
| Ref : Curr Med Res Opin , 23 :1131 , 2007 |
| Abstract : |
| PubMedSearch : He_2007_Curr.Med.Res.Opin_23_1131 |
| PubMedID: 17519080 |
| Title : Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes - Mari_2005_J.Clin.Endocrinol.Metab_90_4888 |
| Author(s) : Mari A , Sallas WM , He YL , Watson C , Ligueros-Saylan M , Dunning BE , Deacon CF , Holst JJ , Foley JE |
| Ref : J Clinical Endocrinology Metab , 90 :4888 , 2005 |
| Abstract : |
| PubMedSearch : Mari_2005_J.Clin.Endocrinol.Metab_90_4888 |
| PubMedID: 15886245 |